JP2023058573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023058573A5 JP2023058573A5 JP2023016697A JP2023016697A JP2023058573A5 JP 2023058573 A5 JP2023058573 A5 JP 2023058573A5 JP 2023016697 A JP2023016697 A JP 2023016697A JP 2023016697 A JP2023016697 A JP 2023016697A JP 2023058573 A5 JP2023058573 A5 JP 2023058573A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 238000006467 substitution reaction Methods 0.000 claims 6
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 4
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 4
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 4
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 4
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 4
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662397736P | 2016-09-21 | 2016-09-21 | |
| US62/397,736 | 2016-09-21 | ||
| US201762466192P | 2017-03-02 | 2017-03-02 | |
| US62/466,192 | 2017-03-02 | ||
| PCT/US2017/052808 WO2018057802A1 (en) | 2016-09-21 | 2017-09-21 | Cd123 binding proteins and related compositions and methods |
| JP2019537049A JP7224289B2 (ja) | 2016-09-21 | 2017-09-21 | Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537049A Division JP7224289B2 (ja) | 2016-09-21 | 2017-09-21 | Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023058573A JP2023058573A (ja) | 2023-04-25 |
| JP2023058573A5 true JP2023058573A5 (OSRAM) | 2023-06-13 |
Family
ID=61690646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537049A Active JP7224289B2 (ja) | 2016-09-21 | 2017-09-21 | Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法 |
| JP2023016697A Pending JP2023058573A (ja) | 2016-09-21 | 2023-02-07 | Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537049A Active JP7224289B2 (ja) | 2016-09-21 | 2017-09-21 | Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11242400B2 (OSRAM) |
| EP (1) | EP3515491A4 (OSRAM) |
| JP (2) | JP7224289B2 (OSRAM) |
| KR (1) | KR102559732B1 (OSRAM) |
| CN (1) | CN109952112B (OSRAM) |
| AU (1) | AU2017331256B2 (OSRAM) |
| BR (1) | BR112019005333A2 (OSRAM) |
| CA (1) | CA3037688A1 (OSRAM) |
| CO (1) | CO2019003951A2 (OSRAM) |
| IL (1) | IL265484B1 (OSRAM) |
| MX (2) | MX2019003225A (OSRAM) |
| MY (1) | MY194290A (OSRAM) |
| NZ (1) | NZ751479A (OSRAM) |
| PH (1) | PH12019500609B1 (OSRAM) |
| SG (1) | SG10202102846SA (OSRAM) |
| UA (1) | UA127450C2 (OSRAM) |
| WO (1) | WO2018057802A1 (OSRAM) |
| ZA (1) | ZA201902323B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| JP7224289B2 (ja) | 2016-09-21 | 2023-02-17 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法 |
| EP3966242A1 (en) * | 2019-05-04 | 2022-03-16 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
| EP3753954A1 (en) * | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells |
| EP4013506A1 (en) * | 2019-08-12 | 2022-06-22 | Aptevo Research and Development LLC | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
| CN110804096B (zh) * | 2019-11-21 | 2021-07-06 | 深圳普瑞金生物药业有限公司 | Cd123单域抗体、核苷酸序列、表达载体及试剂盒 |
| IL294461A (en) * | 2020-01-13 | 2022-09-01 | Aptevo Res & Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| WO2021146328A1 (en) * | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
| CN111171155B (zh) * | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | 抗cd3和cd123双特异性抗体及其用途 |
| US20230273126A1 (en) * | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| CN111732635B (zh) * | 2020-06-22 | 2022-03-22 | 中国医学科学院基础医学研究所 | 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用 |
| US20230391856A1 (en) * | 2020-10-23 | 2023-12-07 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
| US20240301086A1 (en) * | 2020-12-01 | 2024-09-12 | Aptevo Research And Development Llc | Tumor-associated antigens and cd3-binding proteins, related compositions, and methods |
| US20240076392A1 (en) * | 2021-02-17 | 2024-03-07 | Igm Biosciences, Inc. | Anti-cd123 binding molecules and uses thereof |
| JP2024519964A (ja) * | 2021-05-21 | 2024-05-21 | アプティーボ リサーチ アンド デベロップメント エルエルシー | タンパク質治療薬のための投薬レジメン |
| CN116162148B (zh) * | 2021-11-24 | 2025-09-09 | 中山光度生物医药有限公司 | 多特异性配体结合分子及其应用 |
| CN116836282B (zh) * | 2023-02-13 | 2024-03-29 | 北京艺妙神州医药科技有限公司 | 抗体、嵌合抗原受体及其用途 |
| CN117660325B (zh) * | 2024-01-31 | 2024-04-19 | 苏州科为康生物医药科技有限公司 | 一种制备脐带血msc的培养基及其方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| ES2176574T3 (es) | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| AU2002329647A1 (en) | 2001-07-26 | 2003-02-24 | University Of Utah Research Foundation | In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation |
| CN105175535A (zh) | 2002-05-22 | 2015-12-23 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| WO2005058251A2 (en) * | 2003-12-15 | 2005-06-30 | Dendreon Corporation | Hla-dr-specific antibodies, compositions and methods |
| EP1848672A4 (en) | 2005-02-01 | 2009-11-04 | Morphosys Ag | LIBRARIES AND METHOD FOR ISOLATING ANTIBODIES |
| EP1885860A2 (en) * | 2005-05-16 | 2008-02-13 | Morphotek, Inc. | Regulated vectors for selection of cells exhibiting desired phenotypes |
| US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| US7949480B2 (en) | 2006-06-14 | 2011-05-24 | Simphotek, Inc. | Method for determining an interaction between an electromagnetic radiation and a material |
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| EP2187971A2 (en) | 2007-08-01 | 2010-05-26 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| WO2010037836A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| PL2426148T3 (pl) | 2009-04-27 | 2016-01-29 | Kyowa Hakko Kirin Co Ltd | Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US9309322B2 (en) | 2010-11-12 | 2016-04-12 | Scott & White Healthcare (Swh) | Antibodies to tumor endothelial marker 8 |
| MX366813B (es) * | 2012-04-20 | 2019-07-25 | Aptevo Res & Development Llc | Polipeptidos de enlace cd3. |
| EP4053162A1 (en) * | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| JO3568B1 (ar) | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| US10259887B2 (en) * | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| TN2018000324A1 (en) | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| CA2976360A1 (en) * | 2015-02-11 | 2016-08-18 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| US20170349660A1 (en) | 2016-06-01 | 2017-12-07 | Xencor. Inc. | Bispecific antibodies that bind cd123 and cd3 |
| JP7224289B2 (ja) | 2016-09-21 | 2023-02-17 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法 |
| IL294461A (en) | 2020-01-13 | 2022-09-01 | Aptevo Res & Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
-
2017
- 2017-09-21 JP JP2019537049A patent/JP7224289B2/ja active Active
- 2017-09-21 BR BR112019005333-6A patent/BR112019005333A2/pt unknown
- 2017-09-21 AU AU2017331256A patent/AU2017331256B2/en active Active
- 2017-09-21 EP EP17853936.7A patent/EP3515491A4/en active Pending
- 2017-09-21 CA CA3037688A patent/CA3037688A1/en active Pending
- 2017-09-21 KR KR1020197011271A patent/KR102559732B1/ko active Active
- 2017-09-21 UA UAA201904226A patent/UA127450C2/uk unknown
- 2017-09-21 NZ NZ751479A patent/NZ751479A/en unknown
- 2017-09-21 WO PCT/US2017/052808 patent/WO2018057802A1/en not_active Ceased
- 2017-09-21 MY MYPI2019001301A patent/MY194290A/en unknown
- 2017-09-21 CN CN201780069428.3A patent/CN109952112B/zh active Active
- 2017-09-21 US US16/335,561 patent/US11242400B2/en active Active
- 2017-09-21 PH PH1/2019/500609A patent/PH12019500609B1/en unknown
- 2017-09-21 MX MX2019003225A patent/MX2019003225A/es unknown
- 2017-09-21 SG SG10202102846SA patent/SG10202102846SA/en unknown
- 2017-09-21 IL IL265484A patent/IL265484B1/en unknown
-
2018
- 2018-03-22 US US15/933,324 patent/US10676533B2/en active Active
-
2019
- 2019-03-20 MX MX2022015847A patent/MX2022015847A/es unknown
- 2019-04-12 ZA ZA2019/02323A patent/ZA201902323B/en unknown
- 2019-04-19 CO CONC2019/0003951A patent/CO2019003951A2/es unknown
-
2021
- 2021-12-21 US US17/557,440 patent/US11939392B2/en active Active
-
2023
- 2023-02-07 JP JP2023016697A patent/JP2023058573A/ja active Pending
-
2024
- 2024-02-15 US US18/442,779 patent/US12441798B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023058573A5 (OSRAM) | ||
| JP2019531764A5 (OSRAM) | ||
| JP7375122B2 (ja) | ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体 | |
| Surowka et al. | Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins | |
| JP7566766B2 (ja) | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 | |
| CN110914296B (zh) | 改造的Fc片段，包含其的抗体及其应用 | |
| CN106103482B (zh) | 针对pd-l1的人抗体 | |
| JP2024020298A5 (OSRAM) | ||
| JP2020513809A5 (OSRAM) | ||
| WO2021104302A1 (zh) | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2015533853A5 (OSRAM) | ||
| CN107532188A (zh) | Cd20结合分子及其用途 | |
| JP2016505556A5 (OSRAM) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| CA3207270A1 (en) | Human antibodies to pd-1 | |
| JPWO2019129221A5 (OSRAM) | ||
| WO2023208203A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| WO2022188832A1 (zh) | 含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途 | |
| US20220195067A1 (en) | Bispecific antibodies against ceacam5 and cd47 | |
| JP2013519690A5 (OSRAM) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| KR20220104176A (ko) | 순차적 항-cd19 요법 | |
| JPWO2020198531A5 (OSRAM) | ||
| JPWO2020197400A5 (OSRAM) |